Long-term survival after cardiac arrest in hypertrophic cardiomyopathy

Barry J Maron1, Tammy S Haas, Kevin M Shannon

  • 1Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota 55407, USA. hcm.maron@mhif.org

Heart Rhythm
|June 6, 2009
PubMed

Insights

Patients with hypertrophic cardiomyopathy (HCM) experiencing cardiac arrest can achieve long-term survival, even up to 30 years. Many survivors experience few heart failure symptoms, highlighting the unpredictable nature of HCM arrhythmias.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Disease Research

Background:

  • Hypertrophic cardiomyopathy (HCM) patients with aborted cardiac arrest represent a high-risk group with uncertain long-term outcomes.
  • Previous studies have not fully defined the prognosis for HCM patients after major arrhythmic events.

Purpose of the Study:

  • To elucidate the long-term natural history of hypertrophic cardiomyopathy (HCM).
  • To assess the outcomes of HCM patients following cardiac arrest or appropriate implantable cardioverter-defibrillator (ICD) shocks.

Main Methods:

  • Prospective assessment of 39 hypertrophic cardiomyopathy (HCM) patients from the Minneapolis Heart Institute registry.
  • Patients included those who experienced cardiac arrest (n=21) or received an appropriate ICD shock (n=18).

Main Results:

  • 82% of patients (32/39) survived their initial arrhythmic event, with follow-up extending up to 30 years.
  • Of survivors, 47% experienced no further events, while 53% had additional cardiac arrests or ICD interventions.
  • Annual HCM-related mortality was 1.4%, and 91% of survivors had no or mild heart failure symptoms.

Conclusions:

  • Long-term survival (up to 30 years) is possible for hypertrophic cardiomyopathy (HCM) patients after cardiac arrest, with or without ICDs.
  • Disabling heart failure symptoms are uncommon in the long term following these arrhythmic events.
  • The arrhythmogenic substrate in HCM can be unpredictable, remaining dormant for extended periods.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...